Giuliano Filippini Velázquez

We made an effort to review current known mechanisms of AML relapse after alloSCT and their potential implicacions for treatment. It´s just been published and is available for open acces online on Molecular Cancer! @SN_Oncology molecular-cancer.biomedcentral.com/articles/10.11…

Multicenter Real-World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics onlinelibrary.wiley.com/doi/abs/10.100…

@Wang_Yu_Hung @ESHaematology Have fun @Wang_Yu_Hung and learn a lot

✈️ Heading to Lisbon for #ESHMPN2026. Excited for the programme and the chance to meet with colleagues and experts in the field! #MPNsm @ESHaematology

Thrilled to share this collaborative work from GATMO-TC exploring whether HLA-haploidentical related donors may represent a donor choice for patients with severe aplastic anemia. A true multicenter effort from Argentina. doi.org/10.1016/j.jtct…

Smart player, smart coach! My own teacher, former world champion Botvinnik, used to say that you played as well as you deserved to play.

Landmark Paper: in 2002 Silverman et al. published results of the phase III CALGB 9221 trial, showing how azacitidine not only caused sustained improvement in cytopenias but also altered the course of myelodysplastic syndromes. haematologica.org/article/view/1…

Findings support including B-leader status in haploidentical donor selection in Latin America. Read in Blood Global Hematology: ow.ly/fcbF50Yz8vJ #LatinAmerica #HSCT #GVHD

Incredible result so far! Do not underestimate the boost that confidence plays after a strong start. You trust your instincts more, a positive cycle of intuition and performance. Meanwhile, your opponents doubt themselves against you.

These type of curves would have been unimaginable for any haematologists or patients 10years ago. Myeloma is becoming a highly treatable cancer with excellent prognosis Which one is next? Myelofibrosis?

👉 New paper from @TheEBMT practice harmonisation and guidelines committee: practical approaches to defining remission and relapse after allo-HCT in MDS/MPN overlap syndromes — a pragmatic approach to these challenging 🩸 disorders! @TheEBMT_Trainee @CArmstrongHaem #MDSsm #MPNsm gbr01.safelinks.protection.outlook.com/?url=https%3A%…

Asciminib showed increasingly superior efficacy and favorable safety/tolerability vs all IS-TKIs, consistent with the primary analysis. Read in Blood: ow.ly/WOm950YzhjQ #CML

The Iran war has cost in only 31 days, 36 billion USD without counting indirect costs This amounts to around 800,000 USD per minute! Can you imagine what could have been funded with this money instead? No I am not that desperate for grant funding, but my point is research is not expensive, wars are iran-cost-ticker.com

Outpatient low-dose VenAza combined with itraconazole reduced early mortality and hospitalizations while maintaining treatment efficacy. Read in Blood Global Hematology: ow.ly/uORw50YzhVq #AML

Earlier infusion time of CAR T-cell therapy was independently associated with improved PFS in large B-cell lymphoma. Read in Blood: ow.ly/whst50Yyg8j

Really energizing discussion today with the EBMT Trainee Committee! So many ideas from different angles. Excited to turn them into action. Ready to work hard!!💫

Many congratulations to all!!! EBMT future is ever more exciting and look forward to see the contributions of so many fantastic Chairs

CONGRESS | #EBMT26 | PRESENTATION Florent Malard reports final results from the phase III, multicenter, open-label ARES trial, evaluating MaaT013 as a third-line treatment option in patients with treatment-refractory GI-#aGvHD after systemic steroids and ruxolitinib (N = 66). ARES met its primary endpoint, with a Day 28 GI-ORR of 62%, exceeding the pre-established threshold of 22% (p < 0.0001). Most patients had Day 28 GI-CR (38%) or GI-VGPR (20%), with 5% experiencing GI-PR. The all-organ ORR at Day 28 was 64%, and GI-ORR was maintained in 47% at Day 56 and 44% at Month 3. With a median follow-up of 344.5 days, the median OS was not reached; OS was 54% at Month 12, and was higher among Day 28 responders vs non-responders (68% vs 28%). Follow our live feed for more updates: bit.ly/4lyVG9v Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #GvHDsm #MedNews #MedEd @TheEBMT @Florent_Malard @crsa_paris

CONGRESS | #EBMT26 | POSTER Gonzalo Bentolila, Fundacion contra la Leucemia (FUNDALEU), Ciudad Autonoma de Buenos Aires, shares comparative effectiveness of rATG, PTCy and CNI/MTX base for GvHD prophylaxis in matched sibling (MSD) and unrelated donors (MUD) (N=365). Median follow-up was 44 months. Overall, GRFS was similar across strategies (p=0.053). MSD-PTCy independently improved GRFS (HR, 0.47). Adverse predictors included age ≥60 years and high/very-high DRI (HR, 1.43). No prophylaxis strategy independently predicted NRM. Relapse rates were similar with high/very-high DRI. Being the only independent predictor (HR, 1.59). Follow our live feed for more updates: bit.ly/4lyVG9v Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. @TheEBMT #GvHD #MedEd #MedicalCongress @GonzaloBentoli1

Indeed great session! So many opportunities and things to work on. It is also very inspiring to see so many enthusiastic young haematologists

Sunday 22nd of March starting at 10:30, the EBMT trainee day kicks off. It is a truly exciting programme including talks on novel cellular for liver cancer up to how we can reverse ageing using CAR-T cells. Following that there is an excellent joint session with YoungEHA @EHA_Hematology where you can learn about how to get involved. The session will finish with a keynote talk by Jane Apperley on how to build your career on cellular therapies @TheEBMT #EBMT26 @HarrietRoddy @paulmaciocia

#Hematology Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers #lymsm ashpublications.org/bloodadvances/…